论文部分内容阅读
目的观察奥曲肽对顽固性腹水的疗效。方法选择40例顽固性腹水患者,随机分为两组,对照组给予相应的抗感染、维持水电解质平衡、补充白蛋白、利尿及对症支持等常规治疗,治疗组在此基础上加用奥曲肽0.1mg,皮下注射,每8 h一次,共14 d。所有病例均完成2周的疗程。结果治疗组患者2周内腹围平均每天减少量为(2.03±0.43)cm,较对照组的(1.08±0.63)cm减少明显(P<0.05);治疗组24 h尿量(2 087±374.7 ml)及24 h尿钠含量(162.31±98.35 mmo1)较对照组24 h尿量(1 578±175.6 ml)及24 h尿钠含量(68.56±18.38 mmol)明显增加(P<0.05)。结论在常规治疗顽固性腹水的基础上加用奥曲肽,有助于促进顽固性腹水的消退。
Objective To observe the curative effect of octreotide on refractory ascites. Methods Forty patients with refractory ascites were randomly divided into two groups. The control group was given anti-infection, water-electrolyte balance, albumin, diuretic and symptomatic support. The treatment group was given octreotide 0.1 mg, injected subcutaneously once every 8 hours for 14 days. All cases completed two weeks of treatment. Results The mean daily reduction of abdominal circumference was (2.03 ± 0.43) cm in the treatment group within 2 weeks, which was significantly lower than that of the control group (1.08 ± 0.63) cm (P <0.05). The 24 h urine output (2 087 ± 374.7) ml) and 24 h urinary sodium (162.31 ± 98.35 mmo1) were significantly increased (P <0.05) compared with 24 h urine (1578 ± 175.6 ml) and 24 h urinary sodium (68.56 ± 18.38 mmol) in control group. Conclusion In the conventional treatment of intractable ascites based on the use of octreotide, helps to promote refractory ascites.